Skip to main content

Thank you for visiting nature.com. You are using a browser version with limited support for CSS. To obtain the best experience, we recommend you use a more up to date browser (or turn off compatibility mode in Internet Explorer). In the meantime, to ensure continued support, we are displaying the site without styles and JavaScript.

  • Practice Point
  • Published:

Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?

Nature Clinical Practice Urology volume 2, pages 218–219 (2005)Cite this article

boxed-textMcDermott DF et al. (2005) Randomized phase III trial of high-dose interleukin-2 versus subcutaneous interleukin-2 and interferon in patients with metastatic renal cell carcinoma. J Clin Oncol 23: 133–141

Background

This is a preview of subscription content, access via your institution

Access options

Buy this article

  • Purchase on Springer Link
  • Instant access to full article PDF
Buy now

Prices may be subject to local taxes which are calculated during checkout

References

  1. Fyfe G et al. (1995) Results of treatment of 255 patients with metastastic renal cell carcinoma who received high-dose recombinant interleukin-2 therapy. J Clin Oncol 13: 688–696

    Article  CAS  Google Scholar 

  2. Figlin RA et al. (1992) Concomitant administration of recombinant human interleukin-2 and recombinant interferon alfa-2A: an active outpatient regimen in metastatic renal cell carcinoma. J Clin Oncol 10: 414–421

    Article  CAS  Google Scholar 

  3. Atzpodien J et al. (1993) Interleukin-2 in combination with interferon-alpha and 5-fluorouracil for metastatic renal cell cancer. Eur J Cancer 29A (Suppl 5): S6–S8

    Article  Google Scholar 

  4. Dutcher JP et al. (1997) Outpatient subcutaneous interleukin-2 and interferon-alpha for metastatic renal cell cancer: five-year follow-up of the Cytokine Working Group Study. Cancer J Sci Am 3: 157–162

    CAS  PubMed  Google Scholar 

  5. Yang JC et al. (2003) Randomized study of high-dose and low-dose interleukin-2 in patients with metastatic renal cell cancer. J Clin Oncol 21: 3127–3132

    Article  CAS  Google Scholar 

Download references

Acknowledgements

The synopsis was written by Petra Roberts, Associate Editor, Nature Clinical Practice.

Author information

Authors and Affiliations

  1. Associate Professor of Urology and Director of the Renal Cell Carcinoma Working Group at the University of Texas MD Anderson Cancer Center in Houston, TX, USA

    Christopher G Wood

Authors
  1. Christopher G Wood
    View author publications

    You can also search for this author in PubMed Google Scholar

Corresponding author

Correspondence to Christopher G Wood.

Ethics declarations

Competing interests

The author declares no competing financial interests.

Glossary

CI (CONFIDENCE INTERVAL)

An estimated range of values (based on a given set of sample data) that has a specified probability of containing the value being estimated

Rights and permissions

Reprints and permissions

About this article

Cite this article

Wood, C. Can high-dose interleukin-2 be replaced with lower-dose, outpatient regimens for metastatic renal cell carcinoma?. Nat Rev Urol 2, 218–219 (2005). https://doi.org/10.1038/ncpuro0183

Download citation

  • Received:

  • Accepted:

  • Issue Date:

  • DOI: https://doi.org/10.1038/ncpuro0183

Search

Advanced search

Quick links

Nature Briefing

Sign up for the Nature Briefing newsletter — what matters in science, free to your inbox daily.

Get the most important science stories of the day, free in your inbox. Sign up for Nature Briefing